Survivor (n = 128) | Nonsurvivor (n = 27) | Total (n = 155) | P value | |
---|---|---|---|---|
Complications | ||||
Acute respiratory failure | 39 (30.5%) | 23 (85.2%) | 62 (40.0%) | 0.003 |
Septic shock | 1 (0.8%) | 17 (63.0%) | 18 (11.6%) | < 0.001 |
Acute renal failure | 4 (3.1%) | 11 (40.7%) | 15 (9.7%) | < 0.001 |
Altered mental status | 6 (4.7%) | 14 (51.9%) | 20 (12.9%) | < 0.001 |
Bacterial pneumonia | 15 (11.7%) | 13 (48.1%) | 28 (18.1%) | < 0.001 |
Bloodstream infection | 0 | 3 (11.1%) | 3 (1.9%) | 0.006 |
Other infections | 0 | 5 (18.5%) | 5 (3.2%) | < 0.001 |
Antiviral agents | 107 (83.6%) | 25 (92.6%) | 132 (85.2%) | 0.371 |
Oseltamivir treatment | 101 (78.9%) | 24 (88.9%) | 125 (80.6%) | 0.259 |
within 48 hrs of symptom onset | 12 (9.4%) | 4 (14.8%) | 16 (10.3%) | 0.507 |
Broad-spectrum antibiotics | 113 (88.3%) | 26 (96.3%) | 139 (89.7%) | 0.309 |
Corticosteroids | 35 (27.4%) | 17 (63.0%) | 52 (33.5%) | < 0.001 |
Vasopressors | 5 (3.9%) | 23 (85.2%) | 28 (18.1%) | < 0.001 |
Inotropes | 2 (1.6%) | 7 (25.9%) | 9 (5.8%) | < 0.001 |
Neuromuscular blockade | 1 (0.8%) | 7 (25.9%) | 8 (5.2%) | < 0.001 |
Noninvasive ventilation | 19 (14.9%) | 13 (48.1%) | 32 (20.6%) | < 0.001 |
Invasive ventilation | 19 (14.9%) | 24 (88.9%) | 43 (27.7%) | < 0.001 |
Continuous renal replacement therapy | 4 (3.1%) | 13 (48.1%) | 17 (11.0%) | < 0.001 |